latest news releases from the newsroom
CTT to launch new brand dedicated for Airlines and passengers -- Cair
STOCKHOLM, Sweden, March 30, 2004 (PRIMEZONE) -- CTT Systems announced, during the ongoing Hamburg Aircraft Interiors Expo, their new brand - Cair(TM) -- dedicated for the well-being and the health of the passengers and crew.Furthermore it brings a competitive advantage for today's Airlines in their struggle to attract the premium paying passengers and in particular on long haul flights.
Maxim Pharmaceuticals Presents Preclinical Results For Its Novel Vascular Targeting Agent MX116407
STOCKHOLM, Sweden, and SAN DIEGO, March 30, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced research results demonstrating the anti-cancer activity of the Company's MX116407 compounds at the 2004 American Association of Cancer Research (AACR) meeting in Orlando, Florida. Maxim scientists presented key results demonstrating that treatment with MX116407 as a single agent produced tumor regression in lung cancer animal models. MX116407 also produced a statistically significant enhancement of anti-tumor activity when combined with existing cytotoxics that was superior to the activity of other vascular targeting agents currently in clinical development under the auspices of other companies. MX116407 has been shown to induce apoptosis in cancer cells and in several animal efficacy xenograph models, including models of breast cancer, lung cancer and colorectal cancer. MX116407 is being prepared for studies designed to support the initiation of human clinical trials.
OMHEX Selected as Strategic Partner for the National Stock Exchange and Central Securities Depository of Lithuania
STOCKHOLM, Sweden, March 30, 2004 (PRIMEZONE) -- The Lithuanian State Property Fund has decided to select OMHEX as the buyer of 54.5 per cent of the National Stock Exchange of Lithuania (NSEL) and 32 per cent of the Central Securities Depository of Lithuania (CSDL) and invited OMHEX to start negotiations for the conclusion of the share purchase agreement. Together with previously acquired shares, OMHEX will own approximately 85 per cent of NSEL upon completion of the agreement, expected during Q2 2004.
Thousandth Volvo Bus to the Bashi Group in Shanghai
GOTEBORG, Sweden, March 30, 2004 (PRIMEZONE) -- Volvo Buses' joint venture company, Shanghai Sunwin Bus Corporation, recently delivered the thousandth bus to the Bashi Group, the company's largest customer in China. The bus was part of an order for 30 city buses.
Atlas Copco to Acquire Spanish Specialty Equipment Rental Company
STOCKHOLM, Sweden, March 30, 2004 (PRIMEZONE) -- Atlas Copco S.A.E. Holding (Spain) has signed an agreement to acquire Guimera S.A., including its subsidiary S.A.M.M. S.L., both in Spain. The combined companies had annual revenues of MSEK 146.8 (MEUR 16.1) in 2003 and 132 employees. The sales price has not been disclosed.
Crucell Receives NIH Support for Candidate Malaria Vaccine Development
LEIDEN, The Netherlands, March 30, 2004 (PRIMEZONE) -- Dutch biotechnology company Crucell N.V. (Euronext:CRXL) (Nasdaq:CRXL) announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), will support the development of Crucell's candidate malaria vaccine.
Cytomyx Holdings PLC
Cytomyx Licenses Cancer Database to AstraZeneca
CAMBRIDGE, U.K., March 30, 2004 (PRIMEZONE) -- Cytomyx Holdings plc (LSE:CYX), the leading provider of drug discovery products and services, today announces that Clinomics Biosciences Inc, its recently acquired US subsidiary, has licensed its Oncology Cell Signalling Database to AstraZeneca, marking an important milestone for the Company.